Fair Value Measurement

12 Months Ended

Dec. 31, 2023

We enter into derivative instruments for risk management purposes only. We operate internationally and, in the normal course of business, are exposed to fluctuations in interest rates, foreign exchange rates and commodity prices. These fluctuations can increase the costs of financing, investing and operating the business. We use forward contracts, a type of derivative instrument, to manage certain foreign currency exposures.

By nature, all financial instruments involve market and credit risks. We enter into forward contracts with major investment grade financial institutions and have policies to monitor the credit risk of those counterparties. While there can be no assurance, we do not anticipate any material non-performance by any of these counterparties.

Foreign Currency Forward Contracts. We hedge forecasted intercompany sales denominated in foreign currencies through the use of forward contracts. We account for these forward contracts as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in current earnings but are included in accumulated other comprehensive loss. These changes in fair value will be recognized into earnings as a component of sales or cost of sales when the forecasted transaction occurs.

We also enter into forward contracts to exchange foreign currencies for United States dollars in order to hedge our currency transaction exposures. These forward contracts settle each month at month-end, at which time we enter into new forward contracts. We have not designated these forward contracts as hedges and have not applied hedge accounting to them.

The following table presents the notional contract amounts for forward contracts outstanding:


		As of
	FASB ASC Topic 815 Designation	December 31, 2023		December 31, 2022
Forward exchange contracts	Cash flow hedge	$	223,839	$	198,473
Forward exchange contracts	Non-designated	55,789		81,929

The remaining time to maturity as of December 31, 2023 is within two years for hedge designated foreign exchange contracts and approximately one month for non-hedge designated forward exchange contracts.

Statement of comprehensive income (loss) presentation

Derivatives designated as cash flow hedges

Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) ("AOCI") and net earnings on our consolidated statements of comprehensive income (loss) and our consolidated balance sheets:


	Amount of Gain Recognized in AOCI						Consolidated Statements of Comprehensive Income (Loss)							Amount of Gain (Loss) Reclassified from AOCI
	Years Ended							Total Amount of Line Item Presented						Years Ended
Derivative Instrument	2023		2022		2021		Location of amount reclassified	2023		2022		2021		2023		2022		2021

Foreign exchange contracts	$	5,489	$	14,494	$	8,650	Net Sales	$	1,244,744	$	1,045,472	$	1,010,635	$	3,790	$	15,085	$	(5,421)
							Cost of Sales	568,499		474,227		442,599		4,840		939		1,411
Pre-tax gain (loss)	$	5,489	$	14,494	$	8,650								$	8,630	$	16,024	$	(4,010)
Tax expense (benefit)	1,331		3,513		2,090									2,092		3,884		(969)
Net gain (loss)	$	4,158	$	10,981	$	6,560								$	6,538	$	12,140	$	(3,041)

At December 31, 2023, $0.4 million of net unrealized gains on forward contracts accounted for as cash flow hedges, and included in accumulated other comprehensive loss, are expected to be recognized in earnings in the next twelve months.

Derivatives not designated as cash flow hedges

Net losses from derivative instruments not accounted for as hedges and losses on our intercompany receivables on our consolidated statements of comprehensive income (loss) were:


		Years Ended
Derivative Instrument	Location on Consolidated Statements of Comprehensive Income (Loss)	2023		2022		2021

Net loss on currency forward contracts	Selling and administrative expense	$	(891)	$	(240)	$	(451)
Net loss on currency transaction exposures	Selling and administrative expense	$	(1,305)	$	(1,950)	$	(1,832)

Balance sheet presentation

We record these forward foreign exchange contracts at fair value. The following tables summarize the fair value for forward foreign exchange contracts outstanding at December 31, 2023 and 2022:


December 31, 2023	Location on Consolidated Balance Sheet	Asset Fair Value		Liabilities Fair Value		Net Fair Value
Derivatives designated as hedging instruments:
Foreign exchange contracts	Prepaid expenses and other current assets	$	3,761	$	(3,197)	$	564
Foreign exchange contracts	Other long-term liabilities	24		(433)		(409)
		$	3,785	$	(3,630)	$	155

Derivatives not designated as hedging instruments:
Foreign exchange contracts	Other current liabilities	39		(209)		(170)

Total derivatives		$	3,824	$	(3,839)	$	(15)


December 31, 2022	Location on Consolidated Balance Sheet	Asset Fair Value		Liabilities Fair Value		Net Fair Value
Derivatives designated as hedging instruments:
Foreign exchange contracts	Prepaid expenses and other current assets	$	6,757	$	(3,121)	$	3,636
Foreign exchange contracts	Other long-term liabilities	60		(400)		(340)
		$	6,817	$	(3,521)	$	3,296

Derivatives not designated as hedging instruments:
Foreign exchange contracts	Other current liabilities	48		(395)		(347)

Total derivatives		$	6,865	$	(3,916)	$	2,949

Our forward foreign exchange contracts are subject to a master netting agreement and qualify for netting in the consolidated balance sheets.

Fair Value Disclosure. FASB guidance defines fair value and establishes a framework for measuring fair value and related disclosure requirements. This guidance applies when fair value measurements are required or permitted. The guidance indicates, among other things, that a fair value measurement assumes that the transaction to sell an asset or transfer a liability

occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. Fair value is defined based upon an exit price model.

Valuation Hierarchy. A valuation hierarchy was established for disclosure of the inputs to the valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from or corroborated by observable market data through correlation. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. There have been no significant changes in the assumptions.

Valuation Techniques. Assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2023 consist of forward foreign exchange contracts and contingent consideration. The Company values its forward foreign exchange contracts using quoted prices for similar assets. The most significant assumption is quoted currency rates. The value of the forward foreign exchange contract assets and liabilities were valued using Level 2 inputs and are listed in the table above.

The Company values contingent consideration from the In2Bones and Biorez acquisitions using Level 3 inputs. The contingent consideration was recorded at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, revenue volatilities, and projected revenues. The recurring Level 3 fair value measurements of contingent consideration for which the liabilities are recorded include the following significant unobservable inputs as of December 31, 2023:


	Assumptions
Unobservable Input	In2Bones	Biorez

Discount rate	7.62%	12.25%
Revenue volatility	15.49%	21.39%
Projected year of payment	2024-2026	2024-2026

Adjustments to the fair value of contingent consideration relate to the passage of time and changes in market and business assumptions. Changes in the fair value of contingent consideration liabilities for years ended December 31, 2023 and December 31, 2022 are as follows:


	In2Bones		Biorez
Balance at January 1, 2022	$	—	$	—

Purchase price contingent consideration	69,402		114,512

Changes in fair value of contingent consideration	796		1,722

Balance at December 31, 2022	$	70,198	$	116,234

Payments	(13,867)		—

Changes in fair value of contingent consideration	(14,938)		12,517

Balance at December 31, 2023	$	41,393	$	128,751

Contingent consideration of $77.6 million and $92.5 million is included in other current liabilities and other long-term liabilities, respectively, in the consolidated balance sheet at December 31, 2023. Contingent consideration of $18.6 million and $167.8 million is included in other current liabilities and other long-term liabilities, respectively, in the consolidated balance sheet at December 31, 2022.

The carrying amounts reported in our balance sheets for cash and cash equivalents, accounts receivable, accounts payable and variable long-term debt approximate fair value.